Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study
Crizotinib offers therapeutic benefits but is also accompanied by various risks in the form of AEs. Our study findings align with previous clinical observations, and furthermore, we have identified unforeseen serious AEs. This discovery serves as a novel basis for the monitoring of dosages and the identification of risks associated with crizotinib.
Authors
- Yunchang Liu
- Jiang-Dong Sui (ORCID: https://orcid.org/0000-0001-5171-1978)
- Honglei Tu (ORCID: https://orcid.org/0000-0003-3313-9335)
- Huan Zhang (ORCID: https://orcid.org/0000-0001-6914-043X)
- Ying Wang (ORCID: https://orcid.org/0000-0002-9847-4655)
- Lu Zhang (ORCID: https://orcid.org/0000-0003-3469-6096)
- Jieying Yang
- Yunrui Song (ORCID: https://orcid.org/0000-0002-3129-9370)
- Bin Long
- F. Xia
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1186/s40360-025-00859-6
- Citations
- 10
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 15.18
Funders
- National Natural Science Foundation of China